Nova Leah Ltd.

Nova Leah Ltd. specializes in cybersecurity risk management solutions for medical device manufacturers and healthcare providers, enhancing device safety and compliance with regulatory standards. Founded in 2015 in Ireland, Nova Leah Ltd. focuses on cybersecurity solutions for medical devices.

The company was co-founded by Anita Finnegan, Fergal Caffery, and Peter Finnegan, with Anita Finnegan serving as CEO. In December 2021, the company raised EUR 2. 15 million in Seed funding, led by Northwell Ventures, with additional participation from Kernel Capital and Sure Valley Ventures. This funding marked an important milestone in the company’s journey, reflecting its growth and strategic focus on medical cybersecurity.

To date, Nova Leah has completed a total of 4 deals. Nova Leah specializes in cybersecurity risk management solutions tailored for medical device manufacturers and healthcare providers. Their flagship products, SelectEvidence™ and SelectEvaluate®, enhance the cybersecurity posture of connected medical devices and streamline third-party risk management processes. SelectEvidence™ assists manufacturers in managing cyber risks while complying with FDA cybersecurity requirements for devices like defibrillators and pacemakers.

SelectEvaluate® provides healthcare providers with a robust platform to assess and manage cybersecurity risks from third-party vendors, reducing the time for risk assessments from weeks to hours. Their clientele includes manufacturers and healthcare organizations across the United States and Europe, focusing on device safety and regulatory compliance. In 2022, Nova Leah reported revenue of EUR 0 and EBITDA of EUR 0. The company operates primarily on a subscription model for its cybersecurity solutions, engaging clients through direct business-to-business transactions.

Their offerings, SelectEvidence™ and SelectEvaluate®, are integral to clients' risk management strategies, fostering long-term partnerships within the medical device and healthcare sectors. Following the Seed funding round concluded in December 2021, Nova Leah plans to utilize the EUR 2. 15 million raised to expand its medical cybersecurity offerings. This funding will support the development of new products aimed at enhancing the security of medical devices.

The company is also targeting expansion into additional global markets to broaden its client base in the healthcare sector. Specific details regarding upcoming product releases or geographic targets have not been disclosed; however, the focus on strengthening its cybersecurity capabilities underscores its commitment to addressing the growing needs in this critical field.